Skip to main content


  1. Kenneth R.. De Vault, Donald O: Castell, Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease The American Journal of Gastroenterology Vol.94,No.6 1434-1442, 1999.
  2. J C Fang,I Sarosiek, Cholinergic blockade inhibits gastro-oesophageal reflux and transient lower oesophageal sphincter relaxation through a central mechanism GUT Volume 44(5) May 1999 603-607
  3. Daniel Sifrim, Richard Holloway, Effect of Sumatriptan, a 5HT1 Agonist, on the Frequency of Transient Lower Oesophageal Sphincter Relaxations and Gastroesophageal Reflux in Healthy Subjects The American Journal of Gastroenterology Vol.94.No.11.1999 3158-3164
  4. M.A. van Herwaarden, M.Samson, The Motilin Agonist ABT-229, A Potential Drug For The Treatment of GERD? GUT 1999;45 (Suppl V)A40
  5. M.Katschinski, J.Schirra, The Efficacy of Novel 40 mg Extended Release Formulation of Cisapride To Improve Gastrooesophageal Reflux GUT 1999; 45 (Suppl V) A40
  6. T.Havelund, T.Lind, Quality of Life in- Patients With Heartburn But Without Esophagitis Effects of Treatment With Omeprazole. American Journal of Gastroenterology Vol.94,No.7. 1782-1789, 1999.
  7. L.Lundell, P.Miettinen, H.Myrvold A Randomised Comparison Between Omeprazole and Anti-Reflux Surgery in Management of Chronic Gaastroeosophageal Reflux Disease.Report On Five Year Follow-up GUT 1999; 45 (Suppl V), A40
  8. S.Sacher-Huvelin. J.Gurnay ASR And Quality of Life GUT 1999 ;45(Supple V),A40.
  9. McNamara, D;O’Morian,C Gastro-Oesopphageal Reflux Disease and Hp.:an Intricate Relation GUT Volume 45 Supplement No 1 July 113-117
  10. El-Serag, H B;Sonnernberg Corpus Gastritis is protective against reflux oesophagitis GUT, Volume 45(2). August 1999.181-185

11.Justin C.Y. Wu, Joseph J.Y.Sung Prevalence and Distribution of Helicobacter Pylori Gastroesophageal Reflux Disease: A Study from The East.The American Journal of Gastroenterology Vol.94,No.7 1999 1791-1794

  1. Peters FT. Kuipers EJ. The Influence of Helicobacter Pylori on Oesophageal Acid Exposure in GERD Alimentary Pharmacology & Therapeutics 13(7):921-6,1999 Jul.
  2. F.Baldí, R.Cappiello H.Pylori Status And Outcome Of Long-Term PPI Treatment After healing Of Erosiv Oesophagitis GUT 1999; (Suppl V) A41
  3. Khek Yu Ho, Jin Yong Kang Reflux Oesophagitis Patients in Singapore Have Motor and Acid Exposure Abnormalities Similar to Patients in the Western Hemisphere The American Journal of Gasroentrology Vol.94,No.5.1999 1186-1191
  4. Prof. Dr. Tulassay Zsolt A Helicobacter pylori és a gastrooesophagealis reflux betegség European Journal of Gastroenterology & Hepatology Magyar Kiadás III.évf.3.szám 1999 május 81-84
  5. Irene Lluch, Juan F. Ascaso Gastrooesophageal Reflux in Diabetes Mellitus The American Journal of Gastroenterology Vol.94,No,4, 1999, 919-924
  6. R.H.Holloway, M.Horowitz Relationship Between Esophageal Motility and Transit in Patients with Type I Diabetes Mellitus The American Journal of Gastroenterology Vol.94,No.11,1999 3151-3157
  7. Angel Aalvarez-Sanchez, Enrique Rey Does Progesterone Fluctuation Across the Menstrual Cycle Predispose to Gastroesophageal Reflux? The American Journal of Gastroenterology Vol.94,No.6 1999 1469-1471
  8. Prof. Dr. Papp János A Barrett-Oesophagus Gasztroenterológia 1. évfolyam 2. szám 1999. augusztus 33-47
  9. Asadi M, et al. Prospective Multivariate Analysis of Cardia Intestinal Metaplasia (CIM) in Consecutive Patients for Upper Gastroscopy. Gastroenterology 1999; 116(4):A115
  10. Sharma P, et al. Cardia Intestinal Metaplasia(CÍM) Relationship to H.Pylori, Barrett’s Esophagus and Erosive Eesophagitis. Gastroenterology 1999;116(4);A308
  11. Wolf C, et al Cardiac Mucosa-prevalence and Associatios with Intestinal Metaplasia, Age and Helicobacter pylori. Gastroenterology 1999; 116(4):A 356
  12. Sharma,et al. Relativ Risk of Dysplasia for Patients with Intestinal Metaplasia in the Distal Esophagus Versus in Gastric cardia. Gastroenterology 1999 116(4),A:308
  13. Wolf c, et al. Epidemiology and Clinical Characteristics of Intestinal Metaplasia at the Esophagogastric Junction. Gastroenterology 1999;116(4):A356
  14. Vaezi Mf, et al. Cytokeratin Stains to Distinguish Short-Segment Barrett Esophagus from Intestinal Metaplasia of the Esophagogastric Junction. Gastroenterology 1999,116(4)A:340
  15. Ormsby AH, et al. Cytokeratin Subsets Distinguish Barrett’s Esophagus from Gastric Intestinal Metaplasia in Endoscopic Biopsy Specimens. Gastroenterology 1999;116(4):A273
  16. El-Zymaty HMT et al. Cytokeratin Expression in Barrett and Intestinal Metaplasia in the Stomach. Gastroenterology 1999;116(4):A155
  17. Griffel LH,et al. Cellular Phenotype of “cardia type” Barrett’s Epithelium Gastroenterology 1999;116(4):A177
  18. Quinonez N, et al. Prevalence of Barrett’s Esophagus in Guatemalan Hispanics with Reflux Esophagitis. Gastroenterology 1999;116(4):A288
  19. Amarapurkar AD. et al. Barrett’s Esophagus Indian Journal of Pathology and Microbiology. 41 (4):431-5,1998 Oct.
  20. Conio M, et al. Barret’s Esophagus and Adenocarcinoma. Prevalence and Incidence in Olmsted County, Minnesota. Gastroenterology 1999; 116 : A 384
  21. Watson A, et al. Changing Incidence of Columnar-lined (Barrett’s) Oesophagus in the UK. Gastroenterology 1999; 116: A 351
  22. Alan J. Cameron,M.D. Barrett’s Oesophagus : Prevalence and Size of Hiatal Hernia The American Journal of Gastroenterology Vol.94,No.8.1999 2054-2059
  23. C.Pehl, A. Waizenhoefer Effect of Low and High Fat Meals on Lower Esophageal Sphincter Motility and Gastroesophageal Reflux in Healthy Subjects The American Journal of Gastroenterology Vol.94,No5. 1999 1193-1198
  24. Nehra, D;Howell Toxic Bile Acid in Gastro-Oesophageal Reflux Disease: Influence of Gastric Acidity GUT, Volume 44(5).May 1999.598-602
  25. Oberg S. DeMeester The Extent of Barrett’s Esophagus Depends on the Status of the lower Esophageal Sphincter and Degree of Esophageal Acid Exposre Journal of Thoracic& Caediovascular Surgery.117(3):572-80,1999 Mar.
  26. Gostout C J, et al. Long-Segment Barrett’s Esophagus: Is it Associated with Lower Esophageal Sphincter Pressure and Increased Gastroesophageal Reflux Compared to Short Segment Barret’s Esophagus? Gastrointestinal Endoscopy 1999;49(4) :AB 51
  27. Dixon J, et al. Mucus Gel Barrier Absent in Normal Esophagus but Present in Barrett’s Esophagus. Gastroenterology 1999; 116(4) : A 149
  28. Kandil H M, et al. Cyclooxygenase-2(COX-2) Expression in Barrett’s Esophagus. Gastroenterology 1999; 116(49 : A 431
  29. Shirvani V, et al. Cyclooxygenase-2 Expression in Barrett’s Esophagus and Esophageal Adenocarcinoma: Ex Vivo Induction by Bile Salts and Acid Exposure. Gastroenterology 1999; 116(4) A: 337
  30. Poplawsky C, et al. Could Treatment with Low Dose Nonsteroidal Anti-Inflammaory Drugs Help to Accelarate Regression of Barrett’s Esophagus Potential Future Therapeutic Challanges. Gastroenterology 1999; 116(4):A301
  31. Hackelsberger A, et al. Mucosal Proliferation in Specialized Columnar Metaplasia and Intestinal Metaplasia of the Cardia Gastroenterology C1999,116(4):A180
  32. Lord RV, et al. Telomerase Reverse Transcriptase Activation in Barrett’s Esophagus and Barrett’s Adenocarcinomas. Gastroenterology 1999;116(4):A133
  33. Gopal DV, Et al. Risk Factors for Dysplasia in Patients with Barrett’s Esophagus: Results from Multicenter Consortium Gastroenterology 1999; 116(4): A175
  34. Rodica Ouatu-Lascar, Rebecca C. Fitzgerald Differentation and Proliferation in Barrett’s Oesophagus and the Effects of Acid suppression Gastroenterology 1999;Vol. 117; No. 2. 327-335
  35. Yassin R, et al. A Novel, Highly Effective Low Cost Method for Identifying p53 Mutations in Barrett’s Metaplasia. Gastroenterology 1999; 116(4):A363
  36. Casem H, et al. Microsatellite Analises Indentifies an Extended Haplotype at the TNF Locus Associated with Barrett’s Esophagus. Gastroenterology 1999; 116(4): A433
  37. LI AGK et al. The Transcriptional Activator SOX-4 is Overexpressed in Displastic Barrett’s Epithelium and Esophageal Adenocarcioma. Gasrtoenterology 1999; 116(4) : A 453
  38. MacDonald CE, et al. Screening in Patiens with Barrett’s Mucosa. Is There a Need for an Intensive Biopsy Protocol? Gastroenterology 1999; 116(4) : A241
  39. Sontag et al. Barrett’s High Grade Dysplasia: Surviallance Endoscopy Once a Year is Sufficient in Most Patients. Gastroenterology 1999; 116(4):A304
  40. Sontag S J et al. Barrett’s Low Grade Dysplasia and Fear; Yearly Endoscopy is Not Justified Surviellance Every 2-3 Years Detects all Cancers Early. Gastroenterology 1999; 116(4) : A316
  41. Lipscomb S J et al. The Incidence of High Grade Dysplasia and Adenocarcioma Among Patients with Barrett’s Esophagus: a Cohort of 154 Patients Followed for a Total of 471 Patients-Years. Gastroenterology 1999 116(4):A238
  42. Provanzale D. Schmitt C. Barrett’s Esophagus : a New Look at Surveillance Based on Emerging Estimates of Cancer risk. American Journal of Gastroenterology. 94(8):2043-53,1999 Aug.
  43. Robetro De Giorgio, Massimo P. Esophageal and Gastric Nitrc Oxide Synthesizing Innervation in Primary Achalasia The America Journal of Gastroenterology Vol.94,No. 9,1999 2358-2362
  44. Chandra Parkas et al. Botolinum Toxin Injections for Achalasia Symptoms Can Approximate the Short Term Efficacy of a Single Pneumatic Dilation: A Suvival Analysis Approach The American Journal of Gastroenterology Vol.94,No.2,1999 328-333